NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-.
Introduction
The opioid epidemic is a national crisis, but research suggests that some subgroups of the population, such as women, may be more affected than other groups. For example, compared with men, women are more likely to be prescribed painkillers and are likely to be prescribed them in higher doses and to become dependent on them more quickly.1,2 The rate of opioid-related hospitalizations3 and deaths4 has been increasing faster in recent years among women than men. Indeed, in most states in 2014, women had higher opioid-related hospitalization rates than men.5
Among women, some subgroups may be more severely affected by the opioid crisis than others. Substantial differences in opioid use exist based on characteristics of women such as age, race/ethnicity, income, payer, and geography. For example, compared with Black and Hispanic women, White women are more likely to have long-term use of prescription opioids and are likely to have higher rates of drug overdose deaths involving prescription or illegal opioids.6,7 Women aged 65 years and older have a higher prevalence of long-term prescription opioid use for noncancer pain than do women under age 65 years.8 Even within age groups, differences may exist. For instance, among women of reproductive age (15–44 years), prescription opioid use is higher among those with Medicaid than among those with private insurance.9
This Healthcare Cost and Utilization Project (HCUP) Statistical Brief presents statistics on opioid-related hospitalizations among women aged 15 years and older using the 2016 National Inpatient Sample (NIS). The distribution of opioid-related stays by select patient and hospitalization characteristics is presented and contrasted with the distribution for non-opioid-related stays. The types of opioid diagnoses during hospitalization are also provided for select patient characteristics. Finally, rates of opioid-related stays are presented by patient characteristics. Differences greater than 10 percent between estimates are noted in the text.
Findings
Highlights
- The rate of opioid-related stays among women in 2016 was 374.8 per 100,000 population. The rate increased with women’s age, decreased with community-level income, and was highest for White women, followed by Black women.
- Most opioid-related stays among women aged 15–44 years involved abuse/dependence (86 percent). Nearly half of opioid stays among women aged 65 years and older were due to adverse events. Nearly 1 in 10 opioid stays among women aged 45–64 years involved self-harm (more than other age groups).
- Regardless of income level, White women had the highest rate of opioid-related stays, followed by Black women, but the difference between White and Black women decreased from 34 percent higher for White women in the lowest income quartile to 17 percent higher in the highest income quartile.
- In large metropolitan areas, White and Black women had a similar rate of opioid-related stays. However, in rural areas, Black women had a lower rate of opioid stays compared with White women.
- Regardless of age group, the rate of opioid-related stays was lowest among women who resided in the West South Central division.
- The rate of opioid-related stays was higher among older women in the western and north central United States but higher among younger women in the northeastern United States.
Distribution of opioid-related inpatient stays among women by patient characteristics, 2016
Figure 1 presents characteristics of opioid-related versus nonopioid-related stays among women in 2016.
- A higher percentage of opioid-related stays than nonopioid stays were among younger women, White women, and women with Medicaid or who were uninsured.Compared with non-opioid-related stays, a higher percentage of opioid-related stays involved women aged 15–44 years (42.0 vs. 37.0 percent) and 45–64 years (34.9 vs. 23.5 percent), White women (73.3 vs. 62.8 percent), and women with stays billed to Medicaid (35.7 vs. 21.0 percent) or whose stays were not expected to be covered by insurance (“uninsured”; 5.0 vs. 3.2 percent).
- A lower percentage of opioid-related stays than nonopioid stays were among older women, racial/ethnic minority women, women in the highest income quartile, and women with Medicare or private insurance.Compared with non-opioid-related stays, a lower percentage of opioid-related stays involved women aged 65 years and older (23.1 vs. 39.5 percent). Non-White women also constituted a lower percentage of opioid-related than non-opioid-related stays (Black: 12.5 vs. 14.9 percent; Hispanic: 6.2 vs. 11.4 percent; Other race/ethnicity: 3.6 vs. 6.5 percent). A lower percentage of opioid-related than nonopioid stays were among women who resided in the highest income quartile (16.9 vs. 19.5 percent) and women who with stays billed to Medicare (38.3 vs. 43.3 percent) or private insurance (18.5 vs. 30.0 percent).There were no noteworthy differences by patient residence location.
Figure 2 presents the percentage of opioid-related stays among women with a co-occurring mental disorder or pregnancy/childbirth by patient characteristics in 2016. The percentage of non-opioid-related stays with a co-occurring mental disorder or pregnancy/childbirth is provided across all patient subgroups at the top, for comparison.
- The percentage of stays involving a co-occurring mental disorder was more than twice as high for opioid-related stays as for nonopioid stays.More than half of opioid-related stays involved a mental disorder (56.5 percent) compared with only one-fourth of non-opioid-related stays (26.5 percent). The percentage of opioid-related stays with a co-occurring mental disorder was higher among younger women (aged 15–44 years: 59.2 percent; aged 45–64 years: 62.0 percent) than among women aged 65 years and older (43.5 percent). A higher percentage of opioid stays among White women also involved a co-occurring mental disorder (59.1 percent) compared with other racial/ethnic groups (range: 46.4–52.0 percent, depending on the group).
- Nearly one in five opioid-related stays among women of reproductive age involved co-occurring pregnancy/childbirth.Among women aged 18–44 years, 18.4 percent of opioid-related stays involved co-occurring pregnancy/childbirth.
- Co-occurring pregnancy/childbirth with opioid-related stays was more common among women with Medicaid and less common among Black women, women in higher income areas, and women residing in large metropolitan areas.Compared with non-opioid-related stays, the percentage of opioid-related stays that involved a co-occurring pregnancy/childbirth was one-third as high (7.7 vs. 23.5 percent). Women with stays billed to Medicaid had the highest percentage of co-occurring pregnancy/childbirth (16.8 percent vs. 0.6–6.1 percent for other payer types). The percentage of opioid-related stays involving a co-occurring pregnancy/childbirth was lower among Black women (4.8 percent) than among women of other races/ethnicities (8.0–9.9 percent). The percentage of opioid-related stays with a co-occurring pregnancy/childbirth decreased with community-level income, from 8.8 percent in the lowest income quartile to 5.6 percent in the highest income quartile. Conversely, the percentage of opioid-related stays with a co-occurring pregnancy/childbirth increased with rurality of patient residence location, from 6.8 percent in large metropolitan areas to 10.1 percent in micropolitan/noncore areas.
Figure 3 presents the distribution of the type of opioid diagnosis (abuse/dependence, adverse event, or poisoning/self-harm) for opioid-related stays among women by patient characteristics in 2016.
- The percentage of opioid-related stays with an opioid abuse/dependence diagnosis decreased with age, whereas the percentage of stays with an opioid adverse event diagnosis increased with age.The percentage of opioid-related stays with an opioid abuse/dependence diagnosis decreased with age, from 86.4 percent for women aged 15–44 years to 42.2 percent for women aged 65 years and older. Conversely, the percentage of opioid stays with an opioid adverse event diagnosis increased with age, from 8.7 percent for women aged 15–44 years to 49.8 percent for women aged 65 years and older.
- The percentage of opioid-related stays with an opioid abuse/dependence diagnosis decreased with income, whereas the percentage of stays with an opioid adverse event diagnosis increased with income.The percentage of opioid-related stays with an opioid abuse/dependence diagnosis decreased with community-level income, from 75.2 percent for women residing in the lowest income communities to 64.4 percent for women residing in the highest income communities. Conversely, the percentage of opioid stays with an opioid adverse event diagnosis increased with income, from 17.4 percent for women residing in the lowest income communities to 29.6 percent for women residing in the highest income communities.
- The percentage of opioid-related stays with an opioid abuse/dependence diagnosis was higher for women with Medicaid or who were uninsured, whereas the percentage of stays with an opioid adverse event diagnosis was higher for women with Medicare or private insurance.The percentage of opioid-related stays with an opioid abuse/dependence diagnosis was higher for women with Medicaid or who were uninsured (87.0 and 82.6 percent, respectively) than for women with Medicare or private insurance (57.3 and 63.2 percent, respectively). Conversely, the percentage of opioid stays with an opioid adverse event diagnosis was higher for women with Medicare or private insurance (34.1 and 29.2 percent, respectively) than for women with Medicaid or who were uninsured (8.0 and 8.6 percent, respectively).
Population rate of opioid-related inpatient stays among women by patient characteristics, 2016
Figure 4 presents the rate per 100,000 population of opioid-related stays among women overall and by age, race/ethnicity, community-level income, and patient residence in 2016.
- The rate of opioid-related hospitalizations increased with patient age and decreased with community-level income.Overall the rate of opioid-related stays was 374.8 per 100,000 population. The rate of opioid stays was higher among older patients aged 65+ years and aged 45–64 years (426.7 and 405.0 per 100,000 population, respectively) than among patients aged 15–44 years (332.0 per 100,000 population). The rate of opioid-related stays decreased with community-level income, from 484.6 per 100,000 population in the lowest income quartile to 252.2 per 100,000 in the highest income quartile.
- The rate of opioid-related stays was higher among White women than among women of other races/ethnicities.The rate of opioid-related hospitalizations was highest among White women (428.3 per 100,000 population), followed by Black women (379.8 per 100,000 population). The rate was less than half as high among Hispanic women or women of other races/ethnicities (152.2 and 164.1 per 100,000 population, respectively).There were no noteworthy differences by patient residence location.
Figure 5 presents the rate per 100,000 population of opioid-related stays among women by community-level income quartile and race/ethnicity in 2016.
- The rate of opioid-related stays among women decreased by income quartile for each racial/ethnic group.Across racial/ethnic groups, the rate of opioid-related stays among women decreased as community-level income increased. For instance, among White women, the rate decreased from 613.1 per 100,000 population in the lowest income quartile to 282.9 per 100,000 population in the highest income quartile.
- Regardless of income quartile, White women had the highest rate of opioid-related stays.For each income quartile, White women had the highest rate of opioid-related stays compared with other racial/ethnic groups. Black women had the second highest rate of opioid stays in each income quartile. Notably, the difference between White and Black women decreased as community-level income increased, from a 34 percent difference between White and Black women in the lowest income quartile (613.1 vs. 457.5 per 100,000 population) to a 17 percent difference between White and Black women in the highest income quartile (282.9 vs. 242.3 per 100,000 population).
Figure 6 presents the rate per 100,000 population of opioid-related stays among women by patient residence and race/ethnicity in 2016.
- White women had a consistently high rate of opioid-related stays across patient residence type, but the rate of stays for Black women was higher in urban areas than in rural areas.Regardless of patient residence, White women had the highest rate of opioid-related stays compared with other racial/ethnic groups, at over 400 stays per 100,000 population. In large metropolitan areas, the rate of stays was similar for White and Black women (433.9 and 424.8 per 100,000 population, respectively). However, as the rurality of patient residence increased, White women continued to have high rates of opioid-related stays, whereas Black women had lower rates of opioid stays (e.g., 208.8 per 100,000 population in micropolitan and noncore areas).In micropolitan/noncore areas, women of “Other” race/ethnicity had the second highest rate of opioid-related stays (305.5 per 100,000 population) behind White women (403.2 per 100,000 population).
Regional variation in opioid-related inpatient stays among women by age, 2016
Figure 7 provides the population rate of opioid-related inpatient stays among women aged 15–44 years, 45–64 years, and 65 years and older by U.S. census division in 2016. The ratio of each census division rate to the national rate also is provided in the figure and is reflected in the color-coding of the maps.
About Statistical Briefs
Healthcare Cost and Utilization Project (HCUP) Statistical Briefs provide basic descriptive statistics on a variety of topics using HCUP administrative health care data. Topics include hospital inpatient, ambulatory surgery, and emergency department use and costs, quality of care, access to care, medical conditions, procedures, and patient populations, among other topics. The reports are intended to generate hypotheses that can be further explored in other research; the reports are not designed to answer in-depth research questions using multivariate methods.
Data Source
The estimates in this Statistical Brief are based upon data from the HCUP 2016 National Inpatient Sample (NIS). Supplemental sources included population denominator data for use with HCUP databases, derived from information available from Claritas, a vendor that compiles and adds value to data from the U.S. Census Bureau.10
Definitions
Diagnoses, ICD-10-CM/PCS, and major diagnostic categories (MDCs)
The principal diagnosis is that condition established after study to be chiefly responsible for the patient’s admission to the hospital. Secondary diagnoses are concomitant conditions that coexist at the time of admission or develop during the stay. All-listed diagnoses include the principal diagnosis plus these additional secondary conditions.
ICD-10-CM/PCS is the International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System. In October 2015, ICD-10-CM/PCS replaced the ICD-9-CM diagnosis coding system with the ICD-10-CM diagnosis coding system for most inpatient and outpatient medical encounters. There are over 70,000 ICD-10-CM diagnosis codes.
MDCs assign ICD-10-CM principal diagnosis codes to 1 of 25 general diagnosis categories.
Case definition
Opioid-related hospital use was identified using the all-listed ICD-10-CM diagnosis codes shown in Table 1.
Table 1
ICD-10-CM diagnosis codes defining different opioid-related conditions.
Co-occurring mental disorders were defined using the ICD-10-CM codes provided in the separate appendix associated with this Statistical Brief on the HCUP-US website at www.hcup-us.ahrq.gov/reports/statbriefs/sb247-appendix.pdf. Co-occurring pregnancy/childbirth was defined as MDC 14 (pregnancy, childbirth and puerperium).
Types of hospitals included in the HCUP National Inpatient Sample
The National Inpatient Sample (NIS) is based on data from community hospitals, which are defined as short-term, non-Federal, general, and other hospitals, excluding hospital units of other institutions (e.g., prisons). The NIS includes obstetrics and gynecology, otolaryngology, orthopedic, cancer, pediatric, public, and academic medical hospitals. Excluded are long-term care facilities such as rehabilitation, psychiatric, and alcoholism and chemical dependency hospitals. Beginning in 2012, long-term acute care hospitals are also excluded. However, if a patient received long-term care, rehabilitation, or treatment for a psychiatric or chemical dependency condition in a community hospital, the discharge record for that stay will be included in the NIS.
Unit of analysis
The unit of analysis is the hospital discharge (i.e., the hospital stay), not a person or patient. This means that a person who is admitted to the hospital multiple times in 1 year will be counted each time as a separate discharge from the hospital.
Location of patients’ residence
Place of residence is based on the urban-rural classification scheme for U.S. counties developed by the National Center for Health Statistics (NCHS) and based on the Office of Management and Budget (OMB) definition of a metropolitan service area as including a city and a population of at least 50,000 residents:
- Large Central Metropolitan: Counties in a metropolitan area with 1 million or more residents that satisfy at least one of the following criteria: (1) containing the entire population of the largest principal city of the metropolitan statistical area (MSA), (2) having their entire population contained within the largest principal city of the MSA, or (3) containing at least 250,000 residents of any principal city in the MSA
- Large Fringe Metropolitan: Counties in a metropolitan area with 1 million or more residents that do not qualify as large central metropolitan counties
- Medium Metropolitan: Counties in a metropolitan area of 250,000–999,999 residents
- Small Metropolitan: Counties in a metropolitan area of 50,000–249,999 residents
- Micropolitan: Counties in a nonmetropolitan area of 10,000–49,999 residents
- Noncore: Counties in a nonmetropolitan and nonmicropolitan area
Community-level income
Community-level income is based on the median household income of the patient’s ZIP Code of residence. Quartiles are defined so that the total U.S. population is evenly distributed. Cut-offs for the quartiles are determined annually using ZIP Code demographic data obtained from Claritas, a vendor that adds value to data from the U.S. Census Bureau.11 The value ranges for the income quartiles vary by year. The income quartile is missing for patients who are homeless or foreign.
Payer
Payer is the expected payer for the hospital stay. To make coding uniform across all HCUP data sources, payer combines detailed categories into general groups:
- Medicare: includes fee-for-service and managed care Medicare
- Medicaid: includes fee-for-service and managed care Medicaid
- Private Insurance: includes Blue Cross, commercial carriers, and private health maintenance organizations (HMOs) and preferred provider organizations (PPOs)
- Uninsured: includes an insurance status of no insurance, self-pay, no charge, charity, research (e.g., clinical trial or donor), refusal to pay, and no payment
- Other: includes Workers’ Compensation, TRICARE/CHAMPUS, CHAMPVA, Title V, and other government programs
Hospital stays billed to the State Children’s Health Insurance Program (SCHIP) may be classified as Medicaid, Private Insurance, or Other, depending on the structure of the State program. Because most State data do not identify patients in SCHIP specifically, it is not possible to present this information separately.
For this Statistical Brief, when more than one payer is listed for a hospital discharge, the first-listed payer is used.
Division
Division corresponds to the location of the hospital and is one of the nine divisions defined by the U.S. Census Bureau:
- New England: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut
- Middle Atlantic: New York, New Jersey, Pennsylvania
- East North Central: Ohio, Indiana, Illinois, Michigan, Wisconsin
- West North Central: Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, Kansas
- South Atlantic: Delaware, Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida
- East South Central: Kentucky, Tennessee, Alabama, Mississippi
- West South Central: Arkansas, Louisiana, Oklahoma, Texas
- Mountain: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada
- Pacific: Washington, Oregon, California, Alaska, Hawaii
Reporting of race and ethnicity
Data on Hispanic ethnicity are collected differently among the States and also can differ from the census methodology of collecting information on race (White, Black, Asian/Pacific Islander, American Indian/Alaska Native, Other [including mixed race]) separately from ethnicity (Hispanic, non-Hispanic). State data organizations often collect Hispanic ethnicity as one of several categories that include race. Therefore, for multistate analyses, HCUP creates the combined categorization of race and ethnicity for data from States that report ethnicity separately. When a State data organization collects Hispanic ethnicity separately from race, HCUP uses Hispanic ethnicity to override any other race category to create a Hispanic category for the uniformly coded race/ethnicity data element, while also retaining the original race and ethnicity data. This Statistical Brief reports race/ethnicity for the following categories: Hispanic, non-Hispanic White, non-Hispanic Black, and other race/ethnic groups (which includes Asian/Pacific Islander, American Indian/Alaska Native, and non-Hispanic Other).
About HCUP
The Healthcare Cost and Utilization Project (HCUP, pronounced “H-Cup”) is a family of health care databases and related software tools and products developed through a Federal-State-Industry partnership and sponsored by the Agency for Healthcare Research and Quality (AHRQ). HCUP databases bring together the data collection efforts of State data organizations, hospital associations, and private data organizations (HCUP Partners) and the Federal government to create a national information resource of encounter-level health care data. HCUP includes the largest collection of longitudinal hospital care data in the United States, with all-payer, encounter-level information beginning in 1988. These databases enable research on a broad range of health policy issues, including cost and quality of health services, medical practice patterns, access to health care programs, and outcomes of treatments at the national, State, and local market levels.
HCUP would not be possible without the contributions of the following data collection Partners from across the United States:
- Alaska Department of Health and Social Services
- Alaska State Hospital and Nursing Home Association
- Arizona Department of Health Services
- Arkansas Department of Health
- California Office of Statewide Health Planning and Development
- Colorado Hospital Association
- Connecticut Hospital Association
- Delaware Division of Public Health
- District of Columbia Hospital Association
- Florida Agency for Health Care Administration
- Georgia Hospital Association
- Hawaii Health Information Corporation
- Illinois Department of Public Health
- Indiana Hospital Association
- Iowa Hospital Association
- Kansas Hospital Association
- Kentucky Cabinet for Health and Family Services
- Louisiana Department of Health
- Maine Health Data Organization
- Maryland Health Services Cost Review Commission
- Massachusetts Center for Health Information and Analysis
- Michigan Health & Hospital Association
- Minnesota Hospital Association
- Mississippi State Department of Health
- Missouri Hospital Industry Data Institute
- Montana Hospital Association
- Nebraska Hospital Association
- Nevada Department of Health and Human Services
- New Hampshire Department of Health & Human Services
- New Jersey Department of Health
- New Mexico Department of Health
- New York State Department of Health
- North Carolina Department of Health and Human Services
- North Dakota (data provided by the Minnesota Hospital Association)
- Ohio Hospital Association
- Oklahoma State Department of Health
- Oregon Association of Hospitals and Health Systems
- Oregon Office of Health Analytics
- Pennsylvania Health Care Cost Containment Council
- Rhode Island Department of Health
- South Carolina Revenue and Fiscal Affairs Office
- South Dakota Association of Healthcare Organizations
- Tennessee Hospital Association
- Texas Department of State Health Services
- Utah Department of Health
- Vermont Association of Hospitals and Health Systems
- Virginia Health Information
- Washington State Department of Health
- West Virginia Department of Health and Human Resources, West Virginia Health Care Authority
- Wisconsin Department of Health Services
- Wyoming Hospital Association
About the NIS
The HCUP National (Nationwide) Inpatient Sample (NIS) is a nationwide database of hospital inpatient stays. The NIS is nationally representative of all community hospitals (i.e., short-term, non-Federal, nonrehabilitation hospitals). The NIS includes all payers. It is drawn from a sampling frame that contains hospitals comprising more than 95 percent of all discharges in the United States. The vast size of the NIS allows the study of topics at the national and regional levels for specific subgroups of patients. In addition, NIS data are standardized across years to facilitate ease of use. Over time, the sampling frame for the NIS has changed; thus, the number of States contributing to the NIS varies from year to year. The NIS is intended for national estimates only; no State-level estimates can be produced. The unweighted sample size for the 2016 NIS is 7,135,090 (weighted, this represents 35,675,421 inpatient stays).
For More Information
For other information on mental and substance abuse disorders, refer to the HCUP Statistical Briefs located at www.hcup-us.ahrq.gov/reports/statbriefs/sb_mhsa.jsp.
For additional HCUP statistics, visit:
- HCUP Fast Stats at www.hcup-us.ahrq.gov/faststats/landing.jsp for easy access to the latest HCUP-based statistics for health care information topics
- HCUPnet, HCUP’s interactive query system, at www.hcupnet.ahrq.gov/
For more information about HCUP, visit www.hcup-us.ahrq.gov/.
For a detailed description of HCUP and more information on the design of the National Inpatient Sample (NIS) please refer to the following database documentation:
Agency for Healthcare Research and Quality. Overview of the National (Nationwide) Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality. Updated February 2018. www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed February 12, 2018.
Acknowledgments
The authors would like to acknowledge the contributions of Minya Sheng of IBM Watson Health.
APPENDIX. ICD-10-CM codes defining mental disorders and related diagnoses, by category
Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project, Statistical Brief #247: Opioid-Related Hospital Stays Among Women in the United States, 2016 (Weiss AJ, McDermott KW, Heslin KC)
| Code | Mental disorder or related diagnosis |
|---|---|
| Anxiety disorders | |
| F06.4 | Anxiety disorder due to known physiological condition |
| F40.00 | Agoraphobia, unspecified |
| F40.01 | Agoraphobia with panic disorder |
| F40.02 | Agoraphobia without panic disorder |
| F40.10 | Social phobia, unspecified |
| F40.11 | Social phobia, generalized |
| F40.210 | Arachnophobia |
| F40.218 | Other animal type phobia |
| F40.220 | Fear of thunderstorms |
| F40.228 | Other natural environment type phobia |
| F40.230 | Fear of blood |
| F40.231 | Fear of injections and transfusions |
| F40.232 | Fear of other medical care |
| F40.233 | Fear of injury |
| F40.240 | Claustrophobia |
| F40.241 | Acrophobia |
| F40.242 | Fear of bridges |
| F40.243 | Fear of flying |
| F40.248 | Other situational type phobia |
| F40.290 | Androphobia |
| F40.291 | Gynephobia |
| F40.298 | Other specified phobia |
| F40.8 | Other phobic anxiety disorders |
| F40.9 | Phobic anxiety disorder, unspecified |
| F41.0 | Panic disorder [episodic paroxysmal anxiety] |
| F41.1 | Generalized anxiety disorder |
| F41.3 | Other mixed anxiety disorders |
| F41.8 | Other specified anxiety disorders |
| F41.9 | Anxiety disorder, unspecified |
| F42.2 | Mixed obsessional thoughts and acts |
| F42.3 | Hoarding disorder |
| F42.4 | Excoriation (skin-picking) disorder |
| F42.8 | Other obsessive-compulsive disorder |
| F42.9 | Obsessive-compulsive disorder, unspecified |
| F43.11 | Post-traumatic stress disorder, acute |
| F43.12 | Post-traumatic stress disorder, chronic |
| F93.0 | Separation anxiety disorder of childhood |
| F94.0 | Selective mutism |
| R46.6 | Undue concern and preoccupation with stressful events |
| Bipolar disorders | |
| F06.33 | Mood disorder due to known physiological condition with manic features |
| F06.34 | Mood disorder due to known physiological condition with mixed features |
| F30.10 | Manic episode without psychotic symptoms, unspecified |
| F30.11 | Manic episode without psychotic symptoms, mild |
| F30.12 | Manic episode without psychotic symptoms, moderate |
| F30.13 | Manic episode, severe, without psychotic symptoms |
| F30.2 | Manic episode, severe with psychotic symptoms |
| F30.3 | Manic episode in partial remission |
| F30.8 | Other manic episodes |
| F30.9 | Manic episode, unspecified |
| F31.0 | Bipolar disorder, current episode hypomanic |
| F31.10 | Bipolar disorder, current episode manic, without psychotic features, unspecified |
| F31.11 | Bipolar disorder, current episode manic, without psychotic features, mild |
| F31.12 | Bipolar disorder, current episode manic, without psychotic features, moderate |
| F31.13 | Bipolar disorder, current episode manic, without psychotic features, severe |
| F31.2 | Bipolar disorder, current episode manic, severe with psychotic features |
| F31.30 | Bipolar disorder, current episode depressed, mild or moderate severity, unspecified |
| F31.31 | Bipolar disorder, current episode depressed, mild |
| F31.32 | Bipolar disorder, current episode depressed, moderate |
| F31.4 | Bipolar disorder, current episode depressed, severe, without psychotic features |
| F31.5 | Bipolar disorder, current episode depressed, severe, with psychotic features |
| F31.60 | Bipolar disorder, current episode mixed, unspecified |
| F31.61 | Bipolar disorder, current episode mixed, mild |
| F31.62 | Bipolar disorder, current episode mixed, moderate |
| F31.63 | Bipolar disorder, current episode mixed, severe, without psychotic features |
| F31.64 | Bipolar disorder, current episode mixed, severe, with psychotic features |
| F31.71 | Bipolar disorder, in partial remission, most recent episode hypomanic |
| F31.73 | Bipolar disorder, in partial remission, most recent episode manic |
| F31.75 | Bipolar disorder, in partial remission, most recent episode depressed |
| F31.77 | Bipolar disorder, in partial remission, most recent episode mixed |
| F31.81 | Bipolar II disorder |
| F31.89 | Other bipolar disorder |
| F31.9 | Bipolar disorder, unspecified |
| F34.0 | Cyclothymic disorder |
| Depressive disorders | |
| F06.30 | Mood disorder due to known physiological condition, unspecified |
| F06.31 | Mood disorder due to known physiological condition with depressive features |
| F06.32 | Mood disorder due to known physiological condition with major depressive-like episode |
| F32.0 | Major depressive disorder, single episode, mild |
| F32.1 | Major depressive disorder, single episode, moderate |
| F32.2 | Major depressive disorder, single episode, severe without psychotic features |
| F32.3 | Major depressive disorder, single episode, severe with psychotic features |
| F32.4 | Major depressive disorder, single episode, in partial remission |
| F32.8 | Other depressive episodes |
| F32.81 | Premenstrual dysphoric disorder |
| F32.89 | Other specified depressive episodes |
| F32.9 | Major depressive disorder, single episode, unspecified |
| F33.0 | Major depressive disorder, recurrent, mild |
| F33.1 | Major depressive disorder, recurrent, moderate |
| F33.2 | Major depressive disorder, recurrent, severe without psychotic features |
| F33.3 | Major depressive disorder, recurrent, severe with psychotic symptoms |
| F33.41 | Major depressive disorder, recurrent, in partial remission |
| F33.8 | Other recurrent depressive disorders |
| F33.9 | Major depressive disorder, recurrent, unspecified |
| F34.1 | Dysthymic disorder |
| F34.8 | Other persistent mood [affective] disorders |
| F34.81 | Disruptive mood dysregulation disorder |
| F34.89 | Other specified persistent mood disorders |
| F34.9 | Persistent mood [affective] disorder, unspecified |
| F39. | Unspecified mood [affective] disorder |
| O90.6 | Postpartum mood disturbance |
| Disruptive, impulse-control, and conduct disorders | |
| F63.1 | Pyromania |
| F63.2 | Kleptomania |
| F63.81 | Intermittent explosive disorder |
| F63.89 | Other impulse disorders |
| F63.9 | Impulse disorder, unspecified |
| F91.0 | Conduct disorder confined to family context |
| F91.1 | Conduct disorder, childhood-onset type |
| F91.2 | Conduct disorder, adolescent-onset type |
| F91.3 | Oppositional defiant disorder |
| F91.8 | Other conduct disorders |
| F91.9 | Conduct disorder, unspecified |
| Eating disorders | |
| F50.00 | Anorexia nervosa, unspecified |
| F50.01 | Anorexia nervosa, restricting type |
| F50.02 | Anorexia nervosa, binge eating/purging type |
| F50.2 | Bulimia nervosa |
| F50.8 | Other eating disorders |
| F50.81 | Binge eating disorder |
| F50.82 | Avoidant/restrictive food intake disorder |
| F50.89 | Other specified eating disorder |
| F50.9 | Eating disorder, unspecified |
| F98.21 | Rumination disorder of infancy |
| F98.29 | Other feeding disorders of infancy and early childhood |
| F98.3 | Pica of infancy and childhood |
| Obsessive-compulsive disorders | |
| F42 | Obsessive-compulsive disorder |
| F45.21 | Hypochondriasis |
| F45.22 | Body dysmorphic disorder |
| F63.3 | Trichotillomania |
| R46.81 | Obsessive-compulsive behavior |
| Personality disorders | |
| F07.0 | Personality change due to known physiological condition |
| F21. | Schizotypal disorder |
| F60.0 | Paranoid personality disorder |
| F60.1 | Schizoid personality disorder |
| F60.2 | Antisocial personality disorder |
| F60.3 | Borderline personality disorder |
| F60.4 | Histrionic personality disorder |
| F60.5 | Obsessive-compulsive personality disorder |
| F60.6 | Avoidant personality disorder |
| F60.7 | Dependent personality disorder |
| F60.81 | Narcissistic personality disorder |
| F60.89 | Other specific personality disorders |
| F60.9 | Personality disorder, unspecified |
| F68.11 | Factitious disorder with predominantly psychological signs and symptoms |
| F68.12 | Factitious disorder with predominantly physical signs and symptoms |
| F68.13 | Factitious disorder with combined psychological and physical signs and symptoms |
| F68.8 | Other specified disorders of adult personality and behavior |
| F69 | Unspecified disorder of adult personality and behavior |
| Schizophrenia and related disorders | |
| F06.0 | Psychotic disorder with hallucinations due to known physiological condition |
| F06.1 | Catatonic disorder due to known physiological condition |
| F06.2 | Psychotic disorder with delusions due to known physiological condition |
| F20.0 | Paranoid schizophrenia |
| F20.1 | Disorganized schizophrenia |
| F20.2 | Catatonic schizophrenia |
| F20.3 | Undifferentiated schizophrenia |
| F20.5 | Residual schizophrenia |
| F20.81 | Schizophreniform disorder |
| F20.89 | Other schizophrenia |
| F20.9 | Schizophrenia, unspecified |
| F22 | Delusional disorders |
| F23 | Brief psychotic disorder |
| F24 | Shared psychotic disorder |
| F25.0 | Schizoaffective disorder, bipolar type |
| F25.1 | Schizoaffective disorder, depressive type |
| F25.8 | Other schizoaffective disorders |
| F25.9 | Schizoaffective disorder, unspecified |
| F28 | Other psychotic disorder not due to a substance or known physiological condition |
| F29 | Unspecified psychosis not due to a substance or known physiological condition |
| Somatic symptom disorders | |
| F44.4 | Conversion disorder with motor symptom or deficit |
| F44.5 | Conversion disorder with seizures or convulsions |
| F44.6 | Conversion disorder with sensory symptom or deficit |
| F44.7 | Conversion disorder with mixed symptom presentation |
| F45.0 | Somatization disorder |
| F45.1 | Undifferentiated somatoform disorder |
| F45.20 | Hypochondriacal disorder, unspecified |
| F45.29 | Other hypochondriacal disorders |
| F45.41 | Pain disorder exclusively related to psychological factors |
| F45.42 | Pain disorder with related psychological factors |
| F45.8 | Other somatoform disorders |
| F45.9 | Somatoform disorder, unspecified |
| F54 | Psychological and behavioral factors associated with disorders or diseases classified elsewhere |
| F68.10 | Factitious disorder, unspecified |
| Suicidal ideation or attempt | |
| R45.851 | Suicidal ideations |
| T14.91 | Suicide attempt (through FY 2017) |
| T14.91XA | Suicide attempt, initial encounter |
| T36.0X2A | Poisoning by penicillins, intentional self-harm, initial encounter |
| T36.1X2A | Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter |
| T36.2X2A | Poisoning by chloramphenicol group, intentional self-harm, initial encounter |
| T36.3X2A | Poisoning by macrolides, intentional self-harm, initial encounter |
| T36.4X2A | Poisoning by tetracyclines, intentional self-harm, initial encounter |
| T36.5X2A | Poisoning by aminoglycosides, intentional self-harm, initial encounter |
| T36.6X2A | Poisoning by rifampicins, intentional self-harm, initial encounter |
| T36.7X2A | Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter |
| T36.8X2A | Poisoning by other systemic antibiotics, intentional self-harm, initial encounter |
| T36.92XA | Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter |
| T37.0X2A | Poisoning by sulfonamides, intentional self-harm, initial encounter |
| T37.1X2A | Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter |
| T37.2X2A | Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter |
| T37.3X2A | Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter |
| T37.4X2A | Poisoning by anthelminthics, intentional self-harm, initial encounter |
| T37.5X2A | Poisoning by antiviral drugs, intentional self-harm, initial encounter |
| T37.8X2A | Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter |
| T37.92XA | Poisoning by unspecified systemic anti-infective and antiparasitics, intentional self-harm, initial encounter |
| T38.0X2A | Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter |
| T38.1X2A | Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter |
| T38.2X2A | Poisoning by antithyroid drugs, intentional self-harm, initial encounter |
| T38.3X2A | Poisoning by insulin and oral hypoglycemic drugs, intentional self-harm, initial encounter |
| T38.4X2A | Poisoning by oral contraceptives, intentional self-harm, initial encounter |
| T38.5X2A | Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter |
| T38.6X2A | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter |
| T38.7X2A | Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter |
| T38.802A | Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter |
| T38.812A | Poisoning by anterior pituitary hormones, intentional self-harm, initial encounter |
| T38.892A | Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter |
| T38.902A | Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter |
| T38.992A | Poisoning by other hormone antagonists, intentional self-harm, initial encounter |
| T39.012A | Poisoning by aspirin, intentional self-harm, initial encounter |
| T39.092A | Poisoning by salicylates, intentional self-harm, initial encounter |
| T39.1X2A | Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter |
| T39.2X2A | Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter |
| T39.312A | Poisoning by propionic acid derivatives, intentional self-harm, initial encounter |
| T39.392A | Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter |
| T39.4X2A | Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter |
| T39.8X2A | Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter |
| T39.92XA | Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter |
| T40.5X2A | Poisoning by cocaine, intentional self-harm, initial encounter |
| T40.7X2A | Poisoning by cannabis (derivatives), intentional self-harm, initial encounter |
| T40.8X2A | Poisoning by lysergide, intentional self-harm, initial encounter |
| T40.902A | Poisoning by unspecified psychodysleptics, intentional self-harm, initial encounter |
| T40.992A | Poisoning by other psychodysleptics, intentional self-harm, initial encounter |
| T41.0X2A | Poisoning by inhaled anesthetics, intentional self-harm, initial encounter |
| T41.1X2A | Poisoning by intravenous anesthetics, intentional self-harm, initial encounter |
| T41.202A | Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter |
| T41.292A | Poisoning by other general anesthetics, intentional self-harm, initial encounter |
| T41.3X2A | Poisoning by local anesthetics, intentional self-harm, initial encounter |
| T41.42XA | Poisoning by unspecified anesthetic, intentional self-harm, initial encounter |
| T41.5X2A | Poisoning by therapeutic gases, intentional self-harm, initial encounter |
| T42.0X2A | Poisoning by hydantoin derivatives, intentional self-harm, initial encounter |
| T42.1X2A | Poisoning by iminostilbenes, intentional self-harm, initial encounter |
| T42.2X2A | Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter |
| T42.3X2A | Poisoning by barbiturates, intentional self-harm, initial encounter |
| T42.4X2A | Poisoning by benzodiazepines, intentional self-harm, initial encounter |
| T42.5X2A | Poisoning by mixed antiepileptics, intentional self-harm, initial encounter |
| T42.6X2A | Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter |
| T42.72XA | Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter |
| T42.8X2A | Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter |
| T43.012A | Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter |
| T43.022A | Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter |
| T43.1X2A | Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter |
| T43.202A | Poisoning by unspecified antidepressants, intentional self-harm, initial encounter |
| T43.212A | Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter |
| T43.222A | Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter |
| T43.292A | Poisoning by other antidepressants, intentional self-harm, initial encounter |
| T43.3X2A | Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter |
| T43.4X2A | Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter |
| T43.502A | Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter |
| T43.592A | Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter |
| T43.602A | Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter |
| T43.612A | Poisoning by caffeine, intentional self-harm, initial encounter |
| T43.622A | Poisoning by amphetamines, intentional self-harm, initial encounter |
| T43.632A | Poisoning by methylphenidate, intentional self-harm, initial encounter |
| T43.692A | Poisoning by other psychostimulants, intentional self-harm, initial encounter |
| T43.8X2A | Poisoning by other psychotropic drugs, intentional self-harm, initial encounter |
| T43.92XA | Poisoning by unspecific psychotropic drug, intentional self-harm, initial encounter |
| T44.0X2A | Poisoning by anticholinesterase agents, intentional self-harm, initial encounter |
| T44.1X2A | Poisoning by other parasympathomimetics, intentional self-harm, initial encounter |
| T44.2X2A | Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter |
| T44.3X2A | Poisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter |
| T44.4X2A | Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter |
| T44.5X2A | Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter |
| T44.6X2A | Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter |
| T44.7X2A | Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter |
| T44.8X2A | Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter |
| T44.902A | Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter |
| T44.992A | Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter |
| T45.0X2A | Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter |
| T45.1X2A | Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter |
| T45.2X2A | Poisoning by vitamins, intentional self-harm, initial encounter |
| T45.3X2A | Poisoning by enzymes, intentional self-harm, initial encounter |
| T45.4X2A | Poisoning by iron and its compounds, intentional self-harm, initial encounter |
| T45.512A | Poisoning by anticoagulants, intentional self-harm, initial encounter |
| T45.522A | Poisoning by antithrombotic drugs, intentional self-harm, initial encounter |
| T45.602A | Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter |
| T45.612A | Poisoning by thrombolytic drug, intentional self-harm, initial encounter |
| T45.622A | Poisoning by hemostatic drug, intentional self-harm, initial encounter |
| T45.692A | Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter |
| T45.7X2A | Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter |
| T45.8X2A | Poisoning by other primarily systemic and hematological agent, intentional self-harm, initial encounter |
| T45.92XA | Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter |
| T46.0X2A | Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter |
| T46.1X2A | Poisoning by calcium-channel blockers, intentional self-harm, initial encounter |
| T46.2X2A | Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter |
| T46.3X2A | Poisoning by coronary vasodilators, intentional self-harm, initial encounter |
| T46.4X2A | Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter |
| T46.5X2A | Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter |
| T46.6X2A | Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter |
| T46.7X2A | Poisoning by peripheral vasodilators, intentional self-harm, initial encounter |
| T46.8X2A | Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter |
| T46.902A | Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter |
| T46.992A | Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter |
| T47.0X2A | Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter |
| T47.1X2A | Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter |
| T47.2X2A | Poisoning by stimulant laxatives, intentional self-harm, initial encounter |
| T47.3X2A | Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter |
| T47.4X2A | Poisoning by other laxatives, intentional self-harm, initial encounter |
| T47.5X2A | Poisoning by digestants, intentional self-harm, initial encounter |
| T47.6X2A | Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter |
| T47.7X2A | Poisoning by emetics, intentional self-harm, initial encounter |
| T47.8X2A | Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter |
| T47.92XA | Poisoning by unspecified agents primarily affecting the gastrointestinal system, intentional self-harm, initial encounter |
| T48.0X2A | Poisoning by oxytocic drugs, intentional self-harm, initial encounter |
| T48.1X2A | Poisoning by skeletal muscle relaxants, intentional self-harm, initial encounter |
| T48.202A | Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter |
| T48.292A | Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter |
| T48.3X2A | Poisoning by antitussives, intentional self-harm, initial encounter |
| T48.4X2A | Poisoning by expectorants, intentional self-harm, initial encounter |
| T48.5X2A | Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter |
| T48.6X2A | Poisoning by antiasthmatics, intentional self-harm, initial encounter |
| T48.902A | Poisoning by unspecified agents primarily acting on the respiratory system, intentional self-harm, initial encounter |
| T48.992A | Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter |
| T49.0X2A | Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter |
| T49.1X2A | Poisoning by antipruritics, intentional self-harm, initial encounter |
| T49.2X2A | Poisoning by local astringents and local detergents, intentional self-harm, initial encounter |
| T49.3X2A | Poisoning by emollients, demulcents and protectants, intentional self-harm, initial encounter |
| T49.4X2A | Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter |
| T49.5X2A | Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter |
| T49.6X2A | Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter |
| T49.7X2A | Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter |
| T49.8X2A | Poisoning by other topical agents, intentional self-harm, initial encounter |
| T49.92XA | Poisoning by unspecified topical agent, intentional self-harm, initial encounter |
| T50.0X2A | Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter |
| T50.1X2A | Poisoning by loop diuretics, intentional self-harm, initial encounter |
| T50.2X2A | Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter |
| T50.3X2A | Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter |
| T50.4X2A | Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter |
| T50.5X2A | Poisoning by appetite depressants, intentional self-harm, initial encounter |
| T50.6X2A | Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter |
| T50.7X2A | Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter |
| T50.8X2A | Poisoning by diagnostic agents, intentional self-harm, initial encounter |
| T50.902A | Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter |
| T50.992A | Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter |
| T50.A12A | Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter |
| T50.A22A | Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter |
| T50.A92A | Poisoning by other bacterial vaccines, intentional self-harm, initial encounter |
| T50.B12A | Poisoning by smallpox vaccines, intentional self-harm, initial encounter |
| T50.B92A | Poisoning by other viral vaccines, intentional self-harm, initial encounter |
| T50.Z12A | Poisoning by immunoglobulin, intentional self-harm, initial encounter |
| T50.Z92A | Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter |
| T51.0X2A | Toxic effect of ethanol, intentional self-harm, initial encounter |
| T51.1X2A | Toxic effect of methanol, intentional self-harm, initial encounter |
| T51.2X2A | Toxic effect of 2-Propanol, intentional self-harm, initial encounter |
| T51.3X2A | Toxic effect of fusel oil, intentional self-harm, initial encounter |
| T51.8X2A | Toxic effect of other alcohols, intentional self-harm, initial encounter |
| T51.92XA | Toxic effect of unspecified alcohol, intentional self-harm, initial encounter |
| T52.0X2A | Toxic effect of petroleum products, intentional self-harm, initial encounter |
| T52.1X2A | Toxic effect of benzene, intentional self-harm, initial encounter |
| T52.2X2A | Toxic effect of homologues of benzene, intentional self-harm, initial encounter |
| T52.3X2A | Toxic effect of glycols, intentional self-harm, initial encounter |
| T52.4X2A | Toxic effect of ketones, intentional self-harm, initial encounter |
| T52.8X2A | Toxic effect of organic solvents, intentional self-harm, initial encounter |
| T52.92XA | Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter |
| T53.0X2A | Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter |
| T53.1X2A | Toxic effect of chloroform, intentional self-harm, initial encounter |
| T53.2X2A | Toxic effect of trichloroethylene, intentional self-harm, initial encounter |
| T53.3X2A | Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter |
| T53.4X2A | Toxic effect of dichloromethane, intentional self-harm, initial encounter |
| T53.5X2A | Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter |
| T53.6X2A | Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter |
| T53.7X2A | Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter |
| T53.92XA | Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter |
| T54.0X2A | Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter |
| T54.1X2A | Toxic effect of corrosive organic compounds, intentional self-harm, initial encounter |
| T54.2X2A | Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter |
| T54.3X2A | Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter |
| T54.92XA | Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter |
| T55.0X2A | Toxic effect of soaps, intentional self-harm, initial encounter |
| T55.1X2A | Toxic effect of detergents, intentional self-harm, initial encounter |
| T56.0X2A | Toxic effect of lead and its compounds, intentional self-harm, initial encounter |
| T56.1X2A | Toxic effect of mercury and its compounds, intentional self-harm, initial encounter |
| T56.2X2A | Toxic effect of chromium and its compounds, intentional self-harm, initial encounter |
| T56.3X2A | Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter |
| T56.4X2A | Toxic effect of copper and its compounds, intentional self-harm, initial encounter |
| T56.5X2A | Toxic effect of zinc and its compounds, intentional self-harm, initial encounter |
| T56.6X2A | Toxic effect of tin and its compounds, intentional self-harm, initial encounter |
| T56.7X2A | Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter |
| T56.812A | Toxic effect of thallium, intentional self-harm, initial encounter |
| T56.892A | Toxic effect of other metals, intentional self-harm, initial encounter |
| T56.92XA | Toxic effect of unspecified metal, intentional self-harm, initial encounter |
| T57.0X2A | Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter |
| T57.1X2A | Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter |
| T57.2X2A | Toxic effect of manganese and its compounds, intentional self-harm, initial encounter |
| T57.3X2A | Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter |
| T57.8X2A | Toxic effect of inorganic substances, intentional self-harm, initial encounter |
| T57.92XA | Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter |
| T58.02XA | Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter |
| T58.12XA | Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter |
| T58.2X2A | Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter |
| T58.8X2A | Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter |
| T58.92XA | Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter |
| T59.0X2A | Toxic effect of nitrogen oxides, intentional self-harm, initial encounter |
| T59.1X2A | Toxic effect of sulfur dioxide, intentional self-harm, initial encounter |
| T59.2X2A | Toxic effect of formaldehyde, intentional self-harm, initial encounter |
| T59.3X2A | Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter |
| T59.4X2A | Toxic effect of chlorine gas, intentional self-harm, initial encounter |
| T59.5X2A | Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter |
| T59.6X2A | Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter |
| T59.7X2A | Toxic effect of carbon dioxide, intentional self-harm, initial encounter |
| T59.812A | Toxic effect of smoke, intentional self-harm, initial encounter |
| T59.892A | Toxic effect of gases, fumes and vapors, intentional self-harm, initial encounter |
| T59.92XA | Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter |
| T60.0X2A | Toxic effect of organophos and carbamate insecticides, intentional self-harm, initial encounter |
| T60.1X2A | Toxic effect of halogenated insecticides, intentional self-harm, initial encounter |
| T60.2X2A | Toxic effect of insecticides, intentional self-harm, initial encounter |
| T60.3X2A | Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter |
| T60.4X2A | Toxic effect of rodenticides, intentional self-harm, initial encounter |
| T60.8X2A | Toxic effect of other pesticides, intentional self-harm, initial encounter |
| T60.92XA | Toxic effect of unspecified pesticide, intentional self-harm, initial encounter |
| T61.02XA | Ciguatera fish poisoning, intentional self-harm, initial encounter |
| T61.12XA | Scombroid fish poisoning, intentional self-harm, initial encounter |
| T61.772A | Other fish poisoning, intentional self-harm, initial encounter |
| T61.782A | Other shellfish poisoning, intentional self-harm, initial encounter |
| T61.8X2A | Toxic effect of other seafood, intentional self-harm, initial encounter |
| T61.92XA | Toxic effect of unspecified seafood, intentional self-harm, initial encounter |
| T62.0X2A | Toxic effect of ingested mushrooms, intentional self-harm, initial encounter |
| T62.1X2A | Toxic effect of ingested berries, intentional self-harm, initial encounter |
| T62.2X2A | Toxic effect of ingested (parts of) plant(s), intentional self-harm, initial encounter |
| T62.8X2A | Toxic effect of other specified noxious substance eaten as food, intentional self-harm, initial encounter |
| T62.92XA | Toxic effect of unspecified noxious substance eaten as food, intentional self-harm, initial encounter |
| T63.002A | Toxic effect of unspecified snake venom, intentional self-harm, initial encounter |
| T63.012A | Toxic effect of rattlesnake venom, intentional self-harm, initial encounter |
| T63.022A | Toxic effect of coral snake venom, intentional self-harm, initial encounter |
| T63.032A | Toxic effect of taipan venom, intentional self-harm, initial encounter |
| T63.042A | Toxic effect of cobra venom, intentional self-harm, initial encounter |
| T63.062A | Toxic effect of venom of North and South American snake, intentional self-harm, initial encounter |
| T63.072A | Toxic effect of venom of Australian snake, intentional self-harm, initial encounter |
| T63.082A | Toxic effect of venom of African and Asian snake, intentional self-harm, initial encounter |
| T63.092A | Toxic effect of venom of snake, intentional self-harm, initial encounter |
| T63.112A | Toxic effect of venom of gila monster, intentional self-harm, initial encounter |
| T63.122A | Toxic effect of venom of venomous lizard, intentional self-harm, initial encounter |
| T63.192A | Toxic effect of venom of other reptiles, intentional self-harm, initial encounter |
| T63.2X2A | Toxic effect of venom of scorpion, intentional self-harm, initial encounter |
| T63.302A | Toxic effect of unspecified spider venom, intentional self-harm, initial encounter |
| T63.312A | Toxic effect of venom of black widow spider, intentional self-harm, initial encounter |
| T63.322A | Toxic effect of venom of tarantula, intentional self-harm, initial encounter |
| T63.332A | Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter |
| T63.392A | Toxic effect of venom of spider, intentional self-harm, initial encounter |
| T63.412A | Toxic effect of venom of centipede/millipede, intentional self-harm, initial encounter |
| T63.422A | Toxic effect of venom of ants, intentional self-harm, initial encounter |
| T63.432A | Toxic effect of venom of caterpillars, intentional self-harm, initial encounter |
| T63.442A | Toxic effect of venom of bees, intentional self-harm, initial encounter |
| T63.452A | Toxic effect of venom of hornets, intentional self-harm, initial encounter |
| T63.462A | Toxic effect of venom of wasps, intentional self-harm, initial encounter |
| T63.482A | Toxic effect of venom of other arthropod, intentional self-harm, initial encounter |
| T63.512A | Toxic effect of contact with stingray, intentional self-harm, initial encounter |
| T63.592A | Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter |
| T63.612A | Toxic effect of contact with Portuguese man-o-war, intentional self-harm, initial encounter |
| T63.622A | Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter |
| T63.632A | Toxic effect of contact with sea anemone, intentional self-harm, initial encounter |
| T63.692A | Toxic effect of contact with other venomous marine animals, intentional self-harm, initial encounter |
| T63.712A | Toxic effect of contact with venomous marine plant, intentional self-harm, initial encounter |
| T63.792A | Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter |
| T63.812A | Toxic effect of contact with venomous frog, intentional self-harm, initial encounter |
| T63.822A | Toxic effect of contact with venomous toad, intentional self-harm, initial encounter |
| T63.832A | Toxic effect of contact with other venomous amphibians, intentional self-harm, initial encounter |
| T63.892A | Toxic effect of contact with other venomous animals, intentional self-harm, initial encounter |
| T63.92XA | Toxic effect of contact with unspecified venomous animal, intentional self-harm, initial encounter |
| T64.02XA | Toxic effect of aflatoxin, intentional self-harm, initial encounter |
| T64.82XA | Toxic effect of mycotoxin food contaminants, intentional self-harm, initial encounter |
| T65.0X2A | Toxic effect of cyanides, intentional self-harm, initial encounter |
| T65.1X2A | Toxic effect of strychnine and its salts, intentional self-harm, initial encounter |
| T65.212A | Toxic effect of chewing tobacco, intentional self-harm, initial encounter |
| T65.222A | Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter |
| T65.292A | Toxic effect of tobacco and nicotine, intentional self-harm, initial encounter |
| T65.3X2A | Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter |
| T65.4X2A | Toxic effect of carbon disulfide, intentional self-harm, initial encounter |
| T65.5X2A | Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter |
| T65.6X2A | Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter |
| T65.812A | Toxic effect of latex, intentional self-harm, initial encounter |
| T65.822A | Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter |
| T65.832A | Toxic effect of fiberglass, intentional self-harm, initial encounter |
| T65.892A | Toxic effect of other substances, intentional self-harm, initial encounter |
| T65.92XA | Toxic effect of unspecified substance, intentional self-harm, initial encounter |
| T71.112A | Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter |
| T71.122A | Asphyxiation due to plastic bag, intentional self-harm, initial encounter |
| T71.132A | Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter |
| T71.152A | Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter |
| T71.162A | Asphyxiation due to hanging, intentional self-harm, initial encounter |
| T71.192A | Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter |
| T71.222A | Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter |
| T71.232A | Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter |
| X71.0XXA | Intentional self-harm by drowning while in bathtub, initial encounter |
| X71.1XXA | Intentional self-harm by drowning while in swimming pool, initial encounter |
| X71.2XXA | Intentional self-harm by drowning after jump into swimming pool, initial encounter |
| X71.3XXA | Intentional self-harm by drowning in natural water, initial encounter |
| X71.8XXA | Other intentional self-harm by drowning and submersion, initial encounter |
| X71.9XXA | Intentional self-harm by drowning and submersion, unspecified, initial encounter |
| X72.XXXA | Intentional self-harm by handgun discharge, initial encounter |
| X73.0XXA | Intentional self-harm by shotgun discharge, initial encounter |
| X73.1XXA | Intentional self-harm by hunting rifle discharge, initial encounter |
| X73.2XXA | Intentional self-harm by machine gun discharge, initial encounter |
| X73.8XXA | Intentional self-harm by other larger firearm discharge, initial encounter |
| X73.9XXA | Intentional self-harm by unspecified larger firearm discharge, initial encounter |
| X74.01XA | Intentional self-harm by airgun, initial encounter |
| X74.02XA | Intentional self-harm by paintball gun, initial encounter |
| X74.09XA | Intentional self-harm by other gas, air or spring-operated gun, initial encounter |
| X74.8XXA | Intentional self-harm by other firearm discharge, initial encounter |
| X74.9XXA | Intentional self-harm by unspecified firearm discharge, initial encounter |
| X75.XXXA | Intentional self-harm by explosive material, initial encounter |
| X76.XXXA | Intentional self-harm by smoke, fire and flames, initial encounter |
| X77.0XXA | Intentional self-harm by steam or hot vapors, initial encounter |
| X77.1XXA | Intentional self-harm by hot tap water, initial encounter |
| X77.2XXA | Intentional self-harm by other hot fluids, initial encounter |
| X77.3XXA | Intentional self-harm by hot household appliances, initial encounter |
| X77.8XXA | Intentional self-harm by other hot objects, initial encounter |
| X77.9XXA | Intentional self-harm by unspecified hot objects, initial encounter |
| X78.0XXA | Intentional self-harm by sharp glass, initial encounter |
| X78.1XXA | Intentional self-harm by knife, initial encounter |
| X78.2XXA | Intentional self-harm by sword or dagger, initial encounter |
| X78.8XXA | Intentional self-harm by other sharp object, initial encounter |
| X78.9XXA | Intentional self-harm by unspecified sharp object, initial encounter |
| X79.XXXA | Intentional self-harm by blunt object, initial encounter |
| X80.XXXA | Intentional self-harm by jumping from a high place, initial encounter |
| X81.0XXA | Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter |
| X81.1XXA | Intentional self-harm by jumping or lying in front of (subway) train, initial encounter |
| X81.8XXA | Intentional self-harm by jumping or lying in front of moving object, initial encounter |
| X82.0XXA | Intentional collision of motor vehicle with motor vehicle, initial encounter |
| X82.1XXA | Intentional collision of motor vehicle with train, initial encounter |
| X82.2XXA | Intentional collision of motor vehicle with tree, initial encounter |
| X82.8XXA | Other intentional self-harm by crashing of motor vehicle, initial encounter |
| X83.0XXA | Intentional self-harm by crashing of aircraft, initial encounter |
| X83.1XXA | Intentional self-harm by electrocution, initial encounter |
| X83.2XXA | Intentional self-harm by exposure to extremes of cold, initial encounter |
| X83.8XXA | Intentional self-harm by other specified means, initial encounter |
| Trauma- and stressor-related disorders | |
| F43.0 | Acute stress reaction |
| F43.10 | Post-traumatic stress disorder, unspecified |
| F43.20 | Adjustment disorder, unspecified |
| F43.21 | Adjustment disorder with depressed mood |
| F43.22 | Adjustment disorder with anxiety |
| F43.23 | Adjustment disorder with mixed anxiety and depressed mood |
| F43.24 | Adjustment disorder with disturbance of conduct |
| F43.25 | Adjustment disorder with mixed disturbance of emotions and conduct |
| F43.29 | Adjustment disorder with other symptoms |
| F43.8 | Other reactions to severe stress |
| F43.9 | Reaction to severe stress, unspecified |
| F44.0 | Dissociative amnesia |
| F44.1 | Dissociative fugue |
| F44.2 | Dissociative stupor |
| F44.81 | Dissociative identity disorder |
| F44.89 | Other dissociative and conversion disorders |
| F44.9 | Dissociative and conversion disorder, unspecified |
| F94.1 | Reactive attachment disorder of childhood |
| F94.2 | Disinhibited attachment disorder of childhood |
| Miscellaneous mental disorders | |
| F06.8 | Other specified mental disorders due to known physiological condition |
| F09. | Unspecified mental disorder due to known physiological condition |
| F48.1 | Depersonalization-derealization syndrome |
| F48.8 | Other specified nonpsychotic mental disorders |
| F48.9 | Nonpsychotic mental disorder, unspecified |
| F65.0 | Fetishism |
| F65.1 | Transvestic fetishism |
| F65.2 | Exhibitionism |
| F65.3 | Voyeurism |
| F65.4 | Pedophilia |
| F65.51 | Sexual masochism |
| F65.52 | Sexual sadism |
| F65.81 | Frotteurism |
| F65.89 | Other paraphilias |
| F65.9 | Paraphilia, unspecified |
| F93.9 | Childhood emotional disorder, unspecified |
| F99 | Mental disorder, not otherwise specified |
| R45.850 | Homicidal ideations |
Footnotes
- 1
Centers for Disease Control and Prevention. Prescription Painkiller Overdoses: A Growing Epidemic, Especially Among Women. Updated September 4, 2018. https://www
.cdc.gov/vitalsigns /prescriptionpainkilleroverdoses/index.html. Accessed December 10, 2018. - 2
U.S. Food and Drug Administration. Women and Pain Medicines. Updated October 1, 2018. https://www
.fda.gov/ForConsumers /ByAudience /ForWomen/WomensHealthTopics /ucm621707.htm. Accessed December 10, 2018. - 3
Weiss AJ, Bailey MK, O’Malley L, Barret ML, Elixhauser A, Steiner CA. Patient Characteristics and Opioid-Related Inpatient Stays and Emergency Department Visits Nationally and by State, 2014. HCUP Statistical Brief #224. June 2017. Agency for Healthcare Research and Quality, Rockville, MD. www
.hcup-us.ahrq.gov /reports/statbriefs/sb224-Patient-Characteristics-Opioid-Hospital-Stays-ED-Visits-by-State.pdf. Accessed September 26, 2018. - 4
Mack KA, Jones CM, Paulozzi LJ. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. Morbidity and Mortality Weekly Report. 2013;62(26):537–42 [PMC free article: PMC4604783] [PubMed: 23820967].
- 5
Weiss et al., 2017. Op.cit.
- 6
Frenk SM, Porter KS, Paulozzi LJ. Prescription Opioid Analgesic Use Among Adults: United States, 1999–2012. NCHS Data Brief #189. February 2015. Centers for Disease Control and Prevention. www
.cdc.gov/nchs/data/dataBriefs/db189 .pdf. Accessed September 26, 2018 [PubMed: 25714043]. - 7
Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. Morbidity and Mortality Weekly Report. 2018;67(12):349–58 [PMC free article: PMC5877356] [PubMed: 29596405].
- 8
Campbell CI, Weisner C, LeResche L, Ray T, Saunders K, Sullivan MD, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. American Journal of Public Health. 2010;100(12):2541–7 [PMC free article: PMC2978198] [PubMed: 20724688].
- 9
Ailes EC, Dawon AL, Lind JN, Gilboa SM, Frey MT, Broussard CS, et al. Opioid prescription claims among women of reproductive age—United States, 2008–2012. Morbidity and Mortality Weekly Report. 2015;64(2):37–41 [PMC free article: PMC4584597] [PubMed: 25611168].
- 10
Claritas. Claritas Demographic Profile by ZIP Code. https://claritas360
.claritas .com/mybestsegments/. Accessed June 6, 2018. - 11
Claritas. Claritas Demographic Profile by ZIP Code. https://claritas360
.claritas .com/mybestsegments/. Accessed June 6, 2018.
- Weiss AJ (IBM Watson Health), McDermott KW (IBM Watson Health), Heslin KC (AHRQ). Opioid-Related Hospital Stays Among Women, 2016. HCUP Statistical Brief #247. January 2019. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb247-Opioid-Hospital-Stays-Women.pdf
- Review Opioid-Related and Stimulant-Related Adult Inpatient Stays, 2012–2018.[Healthcare Cost and Utilizatio...]Review Opioid-Related and Stimulant-Related Adult Inpatient Stays, 2012–2018.Fingar KR, Owens PL. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. 2006 Feb
- Review Overview of Hospital Stays Among Children and Adolescents, 2019.[Healthcare Cost and Utilizatio...]Review Overview of Hospital Stays Among Children and Adolescents, 2019.Weiss AJ, Liang L, Martin K. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. 2006 Feb
- Review Most Frequent Principal Diagnoses for Inpatient Stays in U.S. Hospitals, 2018.[Healthcare Cost and Utilizatio...]Review Most Frequent Principal Diagnoses for Inpatient Stays in U.S. Hospitals, 2018.McDermott KW, Roemer M. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. 2006 Feb
- Review Hospital Inpatient Stays Related to Opioid Use Disorder and Endocarditis, 2016.[Healthcare Cost and Utilizatio...]Review Hospital Inpatient Stays Related to Opioid Use Disorder and Endocarditis, 2016.Weiss AJ, Heslin KC, Stocks C, Owens PL. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. 2006 Feb
- Review Opioid-Related Inpatient Stays and Emergency Department Visits Among Patients Aged 65 Years and Older, 2010 and 2015.[Healthcare Cost and Utilizatio...]Review Opioid-Related Inpatient Stays and Emergency Department Visits Among Patients Aged 65 Years and Older, 2010 and 2015.Weiss AJ, Heslin KC, Barrett ML, Izar R, Bierman AS. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. 2006 Feb
- Opioid-Related Hospital Stays Among Women in the United States, 2016 - Healthcar...Opioid-Related Hospital Stays Among Women in the United States, 2016 - Healthcare Cost and Utilization Project (HCUP) Statistical Briefs
- BioProject Links for Protein (Select 1576832874) (1)BioProject
- Rumen Uncultured Genome RUG14380Rumen Uncultured Genome RUG14380biosample
- BioSample links for Nucleotide (Select 1810618509) (1)BioSample
Your browsing activity is empty.
Activity recording is turned off.
See more...